Suppr超能文献

靶向脓毒症免疫反应的肠道微生物群代谢产物:机制与疗法

Gut Microbiota Metabolites Targeting the Immune Response in Sepsis: Mechanisms and Therapies.

作者信息

Xu Peng

机构信息

Emergency Department, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, People's Republic of China.

出版信息

Int J Gen Med. 2025 Aug 25;18:4709-4734. doi: 10.2147/IJGM.S539237. eCollection 2025.

Abstract

Sepsis is a global health challenge, affecting millions annually and remaining a leading cause of mortality in intensive care units. Gut microbiota plays a complex role in the onset and progression of sepsis, with its alterations reflecting disease severity. Recently, modulating gut microbiota and its metabolites has emerged as a promising therapeutic strategy for sepsis. This review highlights the role of gut microbiota in sepsis and systematically identifies key immune response targets directly influenced by gut microbiota metabolites, such as short-chain fatty acids (SCFAs), bile acids, and indoleacetic acid, among other important metabolites. Additionally, it offers a full overview of current research on gut microbiota-regulated therapeutic approaches, including fecal microbiota transplantation (FMT) and artificial intelligence (AI) applications. These insights offer a novel perspective for advancing the understanding of sepsis pathogenesis and its treatment.

摘要

脓毒症是一项全球性的健康挑战,每年影响数百万人,并且仍然是重症监护病房中主要的死亡原因。肠道微生物群在脓毒症的发生和发展中起着复杂的作用,其变化反映了疾病的严重程度。最近,调节肠道微生物群及其代谢产物已成为脓毒症一种有前景的治疗策略。本综述强调了肠道微生物群在脓毒症中的作用,并系统地确定了受肠道微生物群代谢产物直接影响的关键免疫反应靶点,如短链脂肪酸(SCFAs)、胆汁酸和吲哚乙酸等其他重要代谢产物。此外,它全面概述了目前关于肠道微生物群调节治疗方法的研究,包括粪便微生物群移植(FMT)和人工智能(AI)应用。这些见解为增进对脓毒症发病机制及其治疗的理解提供了新的视角。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eea2/12396538/a8d0420ea34a/IJGM-18-4709-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验